FIELD: medicine.
SUBSTANCE: invention relates to medicine and can be used to stimulate cognitive function in a healthy individual. Disclosed is a method for stimulating cognitive function in a healthy individual, comprising administering to individual from 2 to 100 mg per day of methylthioninium (MT), optionally divided into 2 or more doses, where MT is administered in the form of a LMTX compound of the following formula 
, where each of HnA and HnB (when present) are protic acids, which may be the same or may be different, and where p = 1 or 2; q = 0 or 1; n = 1 or 2; (p + q) × n = 2 or a hydrate or solvate thereof; and wherein the LMTX compound stimulates basal levels of acetylcholine and synaptophysin in an individual.
EFFECT: invention provides activation of neuron function in healthy subjects by stimulating basal levels of choline and synaptophysin.
27 cl, 1 dwg, 2 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC INTERACTIONS OF LEUKOMETHYLTHIONINIUM | 2020 |
|
RU2834773C2 |
| 3β-(Benzyloxy)-17α-METHYL-PREGN-5-EN-20-ONE FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS | 2019 |
|
RU2796005C2 |
| USE OF A BENZOPYRAN DERIVATIVE FOR THE TREATMENT OF DEMENTIA OF ALZHEIMER'S TYPE ASSOCIATED WITH CALCIUM DYSREGULATION | 2023 |
|
RU2804398C1 |
| MEMANTINE THERAPY FOR ALZHEIMER'S DISEASE OF LOW AND LOW TO MODERATE SEVERITY | 2005 |
|
RU2371173C2 |
| DPP-IV INHIBITORS FOR TREATMENT OF NEURODEGENERATION AND COGNITIVE DISORDERS | 2005 |
|
RU2394570C2 |
| HUMANIZED IMMUNE BODIES IDENTIFYING ALPHA-SINUCLEIN | 2012 |
|
RU2575629C2 |
| REDUCED SYSTEMIC LEVELS OR ACTIVITY OF REGULATORY T-CELLS FOR TREATING DISEASE AND CENTRAL NERVOUS SYSTEM INVOLVEMENT | 2017 |
|
RU2815892C1 |
| TREATING PSYCHOLOGICAL CONDITIONS WITH USING M-MUSCARINIC ANTAGONISTS | 2007 |
|
RU2477634C2 |
| HAEE PEPTIDE MAGNESIUM COMPLEX FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | 2022 |
|
RU2784746C1 |
| HAEE PEPTIDE ZINC COMPLEX FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | 2022 |
|
RU2784319C1 |
